“The upside of including a companion diagnostic is that it improves patient selectivity,” says Sandra Dunn, founder and CEO of Phoenix Molecular Designs, a company focused on finding a treatment for Triple Negative Breast Cancer. “The idea behind it is to personalize treatments for patients. I believe the tests are just one way that the industry is keeping pace with product development in oncology. Patients are reading about these new treatments, and they expect to be matched with the best available treatment. As an industry, we have to be ready to integrate the companion diagnostic piece of the puzzle.”
Read the full article at lifescienceleader.com